iBio, Inc. (IBIO)
NYSEAMERICAN: IBIO · IEX Real-Time Price · USD
1.890
-0.060 (-3.08%)
Apr 17, 2024, 4:00 PM EDT - Market closed
iBio, Inc. Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for iBio, Inc..
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for iBio, Inc..
Recommendation Trends
Rating | Sep '22 | Oct '22 | Nov '22 | Dec '22 | Jan '23 | Feb '23 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Buy | 2 | 1 | 1 | 1 | 1 | 0 |
Hold | 0 | 1 | 1 | 1 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Feb 16, 2023 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades $1,250 → $85 | Buy → Hold | Downgrades | $1,250 → $85 | +4,397.35% | Oct 7, 2022 |
JMP Securities | JMP Securities | Buy Initiates $750 | Buy | Initiates | $750 | +39,582.54% | Nov 29, 2021 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $1,500 | Buy | Initiates | $1,500 | +79,265.08% | Jan 22, 2021 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $1,500 | Buy | Initiates | $1,500 | +79,265.08% | Jan 21, 2021 |
Financial Forecast
Revenue This Year
816.00K
Revenue Next Year
2.04M
from 816.00K
Increased by 150.00%
EPS This Year
-2.45
from -106.20
EPS Next Year
-1.11
from -2.45
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | 840,000 | 2.1M |
Avg | 816,000 | 2.0M |
Low | 784,000 | 2.0M |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | - | 157.4% |
Avg | - | 150.0% |
Low | - | 140.2% |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -2.52 | -1.14 |
Avg | -2.45 | -1.11 |
Low | -2.35 | -1.07 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.